Conference Proceedings
SWATH-MS profiling identifies prognostic factors for progression- free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG)
Sarah A Hayes, Andrew Martin, Sonia Yip, Viive M Howell, Katrin M Sjoquist, Eric Tsobanis, Yoon-Koo Kang, Yung-Jue Bang, Thierry Alcindor, Christopher J O'Callaghan, Niall C Tebbutt, John Simes, David Goldstein, Nick Pavlakis
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
Abstract
Abstract Introduction: Gastric cancer is one of the most common cancers worldwide, and a leading cause of cancer death. Advanced OesophagoGastric cancer (AOGC) has a poor prognosis despite treatment. The P2 INTEGRATE multinational 2:1 (active:placebo) randomized trial demonstrated the activity, on progression-free survival (PFS), of the oral multikinase inhibitor regorafenib (REG) in patients (pts) with refractory AOGC (Pavlakis et al JCO 2016), leading to the P3 INTEGRATE II trial (NCT02773524) currently underway. Here, we sought to identify prognostic protein biomarkers in a discovery analysis of a patient subset from INTEGRATE I. Methods: The discovery ..
View full abstract